COMMUNIQUÉS West-GlobeNewswire

Orion’s collaborator, MSD, expands clinical development program for opevesostat to women’s cancers
21/05/2025
ORION CORPORATION INVESTOR NEWS 21 MAY 2025 at 07.30 EEST Orion’s collaborator, MSD, expands clinical development program for opevesostat to women’s cancers Orion’s collaborator, MSD, has expanded the development [...]
SYNDEO Medical Announces ISO 13485 Certification, Expanding Regulatory Portfolio and Supporting Global Growth Strategy
21/05/2025
ZAVENTEM, Belgium, May 20, 2025 (GLOBE NEWSWIRE) -- SYNDEO Medical, a Belgian-based developer of interventional procedure solutions, is pleased to announce that it has received ISO 13485 certification for its quality [...]
Teva Announces Successful Upsizing and Pricing of $2,300,000,000 (Equivalent) Senior Notes; Proceeds to Repay Existing Debt
20/05/2025
TEL AVIV, Israel, May 20, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“ Teva ”) announced today that it successfully upsized its offering and priced approximately $2,300,000,000 ( [...]
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
20/05/2025
SOUTH SAN FRANCISCO, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the “Company” or “Vaxart”) today announced that the Compensation Committee of the Board of Directors approved certain equity [...]
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
20/05/2025
NOVATO, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare [...]
Segra International Acquires Klonetics to Expand Nursery Capacity and Accelerate Growth
20/05/2025
VANCOUVER, British Columbia, May 20, 2025 (GLOBE NEWSWIRE) -- Segra International (“Segra”), a global leader in cannabis agriculture technology, proudly announces its strategic amalgamation with Klonetics Plant Science [...]
Global Alzheimer’s Platform Foundation Applauds FDA Authorization of the First Blood-Based Diagnostic Test for Assessing Alzheimer’s Disease
20/05/2025
WASHINGTON, May 20, 2025 (GLOBE NEWSWIRE) -- The Global Alzheimer’s Platform Foundation ® (GAP) applauds the FDA's clearance of the first blood test to diagnose Alzheimer’s disease . Fujirebio’s Lumipulse G pTau217/ß- [...]
TrialWire the AI and Algorithm-powered Platform Named a Fierce CRO Award Finalist in the “Outstanding Patient Recruitment and Retention” Category
20/05/2025
TrialWire™ is the risk-share pay-per-enrolled AI and algorithm-powered patient recruitment Platform built on Salesforce Health Cloud for industry-leading patient data and IP security SAN FRANCISCO, May 20, 2025 (GLOBE [...]
Fitch Ratings Agency Upgrades Teva Rating to BB+ Recognizing Successful Execution of Its Pivot to Growth Strategy
20/05/2025
TEL AVIV, Israel, May 20, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals (NYSE and TASE: TEVA) today announced that Fitch Ratings Agency (“Fitch”) has raised the Company's corporate credit rating to BB+, with a stable [...]
Neuphoria Provides First Quarter 2025 Business Updates
20/05/2025
Cash runway into Q3 2026 AFFIRM-1 Phase 3 clinical trial of BNC-210 in social anxiety disorder on track for topline readout in Q3 2025 α7 nicotinic acetylcholine receptor PAM MK-1167 partnered with Merck and in Phase 2 [...]
CooperCompanies’ 2024 Sustainability Report Showcases Efforts that Benefit People and the Planet
20/05/2025
SAN RAMON, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (“Cooper”) (Nasdaq: COO), a leading medical device company, published its 2024 Sustainability Report . The report showcases the company’s initiatives [...]
GENFIT to receive a €26.5 million milestone payment following the approval of pricing and reimbursement of Ipsen’s Iqirvo® in Italy
20/05/2025
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 20, 2025 – GENFIT (Nasdaq and Euronext: GNFT) , a biopharmaceutical company dedicated to improving the lives of patients with rare and [...]
GENFIT va recevoir un paiement d’étape de 26,5 millions d’euros à la suite de l’approbation du prix et du remboursement d’Iqirvo® par Ipsen en Italie
20/05/2025
Lille (France), Cambridge (Massachusetts, Etats-Unis), Zurich (Suisse), le 20 mai, 2025 – GENFIT (Nasdaq et Euronext : GNFT) , société́ biopharmaceutique de stade clinique avancé engagée dans l’amélioration de la vie [...]
RxSight, Inc. to Participate in the Stifel 2025 Virtual Ophthalmology Forum
20/05/2025
ALISO VIEJO, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, [...]
PCI BIotech: Disclosure of voting rights for Chair of the Board
20/05/2025
Oslo, 20 May 2025. PCI Biotech Holding ASA ("PCI Biotech" or the "Company") issue this notification on behalf of Hans Peter Bøhn, Chair of the Board of Directors. Hans Peter Bøhn is chair of PCI Biotech’s board of [...]
Ceribell to Participate in the William Blair 45th Annual Growth Stock Conference
20/05/2025
SUNNYVALE, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological [...]
INVO Fertility Announces First Quarter 2025 Financial Results
20/05/2025
Company now exclusively focused on the growing fertility market following the April 2025 announcement to divest a majority stake in Naya Therapeutics SARASOTA, Fla., May 20, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc [...]
HonorHealth Research Institute patient with advanced skin cancer in remission for more than a year following clinical trial of Werewolf Therapeutics' investigational novel conditionally activated IL-2 pro-drug WTX-124
20/05/2025
There are nearly 40,000 U.S. cases of cutaneous squamous cell carcinoma each year that advance to stages that are difficult to treat and life-threatening Skin Cancer Awareness Month in May shines a spotlight on the [...]
Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-002, its Novel Half-life Extended Anti-IL-17A/F Antibody
20/05/2025
Pharmacokinetic and safety data from healthy volunteers anticipated around YE 2025 On track to initiate a Phase 2 study in 1H 2026 ORKA-002 preclinical data demonstrate the potential for dosing two to three times per [...]

Pages